Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Abingdon Health Plc | LSE:ABDX | London | Ordinary Share | GB00BLF79J41 | ORD 0.025P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 7.25 | 333 | 07:44:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 7.00 | 7.50 | 7.25 | 7.25 | 7.25 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Chemicals & Chem Preps, Nec | 6.14M | -1.27M | -0.0052 | -13.94 | 17.63M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 10:17:25 | O | 8 | 7.005 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 19/11/2024 | 12:00 | UK RNS | Abingdon Health PLC Result of AGM |
| 19/11/2024 | 07:00 | UK RNS | Abingdon Health PLC AGM Statement |
| 21/10/2024 | 15:00 | UK RNS | Abingdon Health PLC Notice of AGM |
| 15/10/2024 | 13:18 | ALNC |  Abingdon Health to launch commercial activities in the US |
| 15/10/2024 | 06:00 | UK RNS | Abingdon Health PLC Opening of US commercial office and laboratory |
| 08/10/2024 | 13:24 | ALNC | Abingdon Health narrows annual loss as revenue grows more than 50% |
| 08/10/2024 | 06:00 | UK RNS | Abingdon Health PLC Final Results |
| 04/10/2024 | 06:00 | UK RNS | Abingdon Health PLC Notice of Results |
| 29/8/2024 | 06:00 | UK RNS | Abingdon Health PLC Results of the Retail Offer |
| 27/8/2024 | 08:26 | UK RNS | Abingdon Health PLC TR - 1 |
Abingdon Health (ABDX) Share Charts1 Year Abingdon Health Chart |
|
1 Month Abingdon Health Chart |
Intraday Abingdon Health Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 10/7/2024 | 07:42 | World's First Saliva Pregnancy Self-Test | 4 |
| 21/3/2024 | 08:49 | Abingdon Health: Lateral Flow Diagnostics | 1,585 |
| 21/12/2022 | 15:52 | freeFor all rampngFree | 69 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 10:17:26 | 7.01 | 8 | 0.56 | O |
| 08:15:46 | 7.50 | 325 | 24.38 | O |
| 2024-11-20 14:22:37 | 7.08 | 40,000 | 2,830.00 | O |
| 2024-11-20 12:50:09 | 7.01 | 98 | 6.86 | O |
| Top Posts |
|---|
Posted at 21/11/2024 08:20 by Abingdon Health Daily Update Abingdon Health Plc is listed in the Chemicals & Chem Preps, Nec sector of the London Stock Exchange with ticker ABDX. The last closing price for Abingdon Health was 7.25p.Abingdon Health currently has 243,112,894 shares in issue. The market capitalisation of Abingdon Health is £17,625,685. Abingdon Health has a price to earnings ratio (PE ratio) of -13.94. This morning ABDX shares opened at 7.25p |
Posted at 10/7/2024 07:42 by tia01 So after yesterday does anyone believe a discounted share placement coming!. Revenue growing but cash pile reducing.I’d say definitely a cash raise somewhere to fund expansion. Cash is king |
Posted at 17/5/2024 11:59 by z1co York, U.K. 15th May 2024: Abingdon Health plc (AIM: ABDX), a leading international lateral flow Contract Development and Manufacturing Organisation (CDMO), announces the launch of Boots own-brand, saliva pregnancy self-test across the UK and online, in partnership with Salignostics and Crest Medical.On 20th March 2024, Abingdon Health announced the launch of the first two Boots branded self-tests - Iron and Vitamin D deficiency - in-store and online at boots.com. In another step toward strengthening this partnership with Boots, Abingdon Health is now pleased to announce the launch of the first ever saliva pregnancy test under the Boots own brand range. The test is being made available in store and online at boots.com from Spring 2024 onwards. This product launch allows more people to access a new way of testing for pregnancy. With the UK pregnancy self-test market expected to reach USD $56.7 million by 20331, this provides a strategic opportunity to launch, on an own-brand basis, an innovative product in this growing market with the UK's leading health and beauty retailer. With general consumer adoption of self-tests on the rise (US $7.89 billion in 2023)2, and a robust pipeline of products within its CRO/CDMO offering, Abingdon Health is well positioned to continue developing OEM retail relationships within the UK and Europe as a value-add, innovative Private Label Supplier (PLS). |
Posted at 15/3/2024 15:26 by daz TimboI thought the outlook statement was very misleading. Last year ABDX had a strong H2 weighting and it looks to be the same this year, so to say H2 will be materially ahead of H1 is meaningless. A comparison with H2 last year would have given investors a much better insight. Growth will not be 116% in H2 but I want to know 1. Will it be positive and 2. If positive, by roughly how much 20/30/40% etc. Also, the cash outflow in H1 was £1.238m and they only have £2m cash left. While the burn rate will be lower in H2, without better guidance, it becomes impossible for private investors to make an informed view on the H2 outflow. No doubt Brokers will have been greater insight but it's not much help to me. Based on the lack of clarity, I can't dismiss the need for another fund raise. |
Posted at 14/3/2024 11:30 by timbo003 How times change!* Confirmation today that no additional funding required * Robust current trading * top of the leader board today * Last (very substantial) director purchases (at the last placing) were at level 2.5 X the current share price and no comments? |
Posted at 14/10/2023 13:42 by timbo003 Register for the seminar mentioned in the previous post (which includes a presentation from ABDX) here: |
Posted at 14/10/2023 10:45 by sharesoc ShareSoc is holding its first hybrid event in London on 19th Oct. Hear from Abingdon Health (ABDX) and other healthcare companies like Tristel Plc (TSTL), Inspiration Healthcare Group (IHC), Creo Medical Group (CREO) and GENincode (GENI). Attend in-person or online.📍 |
Posted at 28/6/2023 21:53 by criticalthinker1 Had to pay my road tax today. Long story short. So ventured into a smaller Superdrug outlet. No Salistick on display. The representative said that she knew of them and they were being supplied to the larger shops first and the smaller ones later. A recent delivery was awaiting shop distribution of latest delivery ...are we there?...That's a distribution factor I suppose. Anyways. Ongoing. Spit or pee? That is the question! And the price point is well within the parameters of the markets. One of the clear blue 29.99. Check it out for yourself. Even if you identify as a potato you can check out if you are impregnated by a mouth swab as opposed to a urinal splatter test. |
Posted at 12/6/2023 20:23 by criticalthinker1 I'm guessing that is to sell a tranche of your shares?.....always good to take a cut...but I'm holding and adding.Your next target would be a 15% rise on today's rise, but depending on the spread that the brokers decide on due to volume (buys and sells), so about half today's rise. But depending when you bought. My opinion fwiw....and note I raise the Novacyt point...and note how since our listing (note the price then to now and since then the increased ipr/licenses and market awareness) we have been exonerated of any profiteering or wrongdoing re the 'covid' debacle of testing et al! And one of our NEOs has a significant holding with no intention to sell and put some 3m in trust. This company has the values I look for, not many out there. Leadership, vision, ongoing licensing, ipr updates re the smartphone feature, board investment, a couple other products aside from Salistick that I think will have there moment recognised... The MHRA has caused disruption to UK drug/supporting paraphernalia products and the vast economy they support, with poor excuses. Emma Walmsley has also said such. Bandits imo. So given my cynical view of the financial world and the strings they hold, I think we have paid our dues re negative media and I'd say I'm looking at the next target to be just over 20p within 2 weeks, assuming Salistick product launch and then that garnering Abingdon market awareness, and Mr Yates purchase at 25p. Then maybe a short (profit taking) breather, down to about 16p then up to.....well 25p and then £s. All best. This is my opinion and my hope! |
Posted at 12/6/2023 19:07 by criticalthinker1 Buckled in. Seen this price type graph (last 6 months) before. Imo its about fundamentals being seen early by some who can see the mc value potential, so they buy and hold. Some think they get it so buy early ish and sell, probably at last little 'peak', thinking mc value reached.Each to their own. So they sell and share price goes down, but the floor is going up and up. Reminds me of the Novacyt days. Note Novacyts test was a 'period' of making hay whilst the 'pandemic' was, well actually an epidemic from the early days, and that's fact. This has got legs. And not just a one trick pony... Salistik is a game changer imo. This product unless superceded by a better product is going to own the pregnancy test market for a considerable time! Globally? Well atleast we got the rights to the UK and Ireland. It's also worth noting that we are entering the period of increased pregnancies in certain places due to increased testosterone due to sunshine. So the product release date (got to be imminent) is going to see a sustained increase in sales. Not sure if the marketing department has done this by design or accident, but as long as the product is readily available...hold onto your hats! |
Posted at 20/9/2022 07:54 by shallow pockets It's going to get a little neurotic for those still in this stock as we head to 4p. The likes of Bigjock36 shouldn't get any hopes up though, when a price spike occurs. There will be some flies buzzing around the carcass of this management destroyed company from time to time seeking to buy the company as the share price sinks lower, thinking it looks cheap and that the book value outweighs the share price, until they realise in DD that there are no proper assets other than cash, which is dwindling heavily by the day, mostly to overpay the Board,, and that the share price, far from being cheap now, was just ridiculously expensive previously, with the Board clueless and unable to grab the once in a lifetime opportunity that was infront of it. Show us their qualifications to ever have done so.Its a shame that Bigjock36 and his fellow bulls didn't make this analysis much earlier before they lost all of their investment. Stay short. Target 4p. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
